Search results for "EGFR mutations"

showing 3 items of 3 documents

LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology

2021

Abstract Objectives The aim of LungBEAM was to determine the value of a novel epidermal growth factor receptor (EGFR) mutation test in blood based on BEAMing technology to predict disease progression in advanced non‐small cell lung cancer (NSCLC) patients treated with first‐ or second‐generation EGFR‐tyrosine kinase inhibitors (EGFR‐TKIs). Another goal was to monitor the dynamics of EGFR mutations, as well as to track EGFR exon 20 p.T790M (p.T790M) resistance during treatment, as critical indicators of therapeutic efficacy and patient survival. Methods Stage IV NSCLC patients with locally confirmed EGFR‐TKI sensitizing mutations (ex19del and/or L858R) in biopsy tissue who were candidates to…

OncologyMaleCancer ResearchPulmons - Càncer - PrognosiLung Neoplasms:técnicas de investigación::técnicas genéticas::análisis de secuencias::análisis de secuencias de ADN::análisis de mutaciones del ADN [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]medicine.disease_causeBEAMingExonnon-small cell lung carcinomaInterquartile rangeCarcinoma Non-Small-Cell LungEpidermal growth factor receptorProspective StudiesRC254-282Research ArticlesMutationmedicine.diagnostic_testbiologyHazard ratioNeoplasms. Tumors. Oncology. Including cancer and carcinogens:Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma Bronchogenic::Carcinoma Non-Small-Cell Lung [DISEASES]ErbB ReceptorsOncology:Investigative Techniques::Genetic Techniques::Sequence Analysis::Sequence Analysis DNA::DNA Mutational Analysis [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]FemaleADN - AnàlisiResearch Articlemedicine.medical_specialty:Otros calificadores::/diagnóstico [Otros calificadores]Internal medicineBiopsymedicineHumansRadiology Nuclear Medicine and imagingLiquid biopsyAgedliquid biopsybusiness.industryClinical Cancer Research:neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES]EGFR mutationsConfidence intervalnon‐small cell lung carcinomarespiratory tract diseases:Neoplasms [DISEASES]Mutationbiology.proteinbusinessPulmons - Càncer - Tractament
researchProduct

Gefitinib in lung cancer therapy. Clinical results, predictive markers of response and future perspectives.

2009

Over the past few years, epidermal growth factor receptor has emerged as one of the most important targets in tumorgenesis and several drugs targeting signal transduction pathways have been developed. The first among these agents to be approved for the treatment of NSCLC was gefitinib, a potent, selective and reversible inhibitor of HER1/EGFR tyrosine kinase activity. The review summarizes its clinical development and the new therapeutic options, with particular focus on predictive markers of susceptibility to this drug.

DrugOncologyCancer Researchmedicine.medical_specialtyLung Neoplasmsmolecular markersmedia_common.quotation_subjectgefitinibAntineoplastic AgentsGefitinibcancer therapyGefitinibCarcinoma Non-Small-Cell LungInternal medicinetyrosine kinase inhibitorsmedicineAnimalsHumansgefitinib; non-small cell lung cancer (NSCLC); epidermal growth factor receptor (HER1/EGFR); tyrosine kinase inhibitors; target therapy; molecular markers; EGFR mutationsEpidermal growth factor receptorLung cancermedia_commonPharmacologyClinical Trials as Topicbiologybusiness.industrytarget therapymedicine.diseaseEGFR mutationsepidermal growth factor receptor (HER1/EGFR)ErbB Receptorsnon-small cell lung cancer (NSCLC)OncologyQuinazolinesbiology.proteinMolecular MedicineSignal transductionbusinessBiomarkersEgfr tyrosine kinaseSignal Transductionmedicine.drug
researchProduct

Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors

2014

Abstract: Introduction: Treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) yields tumour responses in non-small cell lung cancer (NSCLC) patients harbouring activating EGFR mutations. However, even in long-lasting responses, resistance to EGFR TKIs invariably occurs. Areas covered: This review examines resistance mechanisms to EGFR TKI treatment, which mainly arise from secondary EGFR mutations. Other resistance-inducing processes include mesenchymal-epithelial transition factor (MET) amplification, epithelial-mesenchymal transformation, phenotypic change from NSCLC to small-cell lung carcinoma, and modifications in parallel signalling pathways. Current…

Lung NeoplasmsSettore MED/06 - Oncologia MedicaAfatinibNovel therapeutic strategiesLapatinibmedicine.disease_causeNSCLCT790Mchemistry.chemical_compoundErbB ReceptorsCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansRadiology Nuclear Medicine and imagingEpidermal growth factor receptorProtein Kinase InhibitorsEGFR inhibitorsbiologybusiness.industryEGFR mutations; TKI inhibitors resistance; NSCLC; New drugs; Novel therapeutic strategiesGeneral MedicineNew drugEGFR mutationsCombined Modality TherapyDacomitinibrespiratory tract diseasesErbB ReceptorsNew drugsOncologychemistryDrug Resistance NeoplasmCancer researchbiology.proteinKRASHuman medicineEGFR mutationbusinessmedicine.drugTKI inhibitors resistanceCancer Treatment Reviews
researchProduct